The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) ROC %: 0.00% (As of . 20)


DHA:IBNSINA The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
20 GF Score
Price BDT318.20
View Full Analysis

What is The IBN SINA Pharmaceutical Industry ROC %?

The IBN SINA Pharmaceutical Industry DHA:IBNSINA +0.47% 20 ROC % is 0.00% as of . 20. GuruFocus rates DHA:IBNSINA with a GF Score™ of 20/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The IBN SINA Pharmaceutical Industry's annualized return on capital (ROC %) for the quarter that ended in . 20 was 0.00%.

As of today (2026-06-26), The IBN SINA Pharmaceutical Industry's WACC % is 0.00%. The IBN SINA Pharmaceutical Industry's ROC % is 0.00% (calculated using TTM income statement data). The IBN SINA Pharmaceutical Industry earns returns that do not match up to its cost of capital. It will destroy value as it grows.

The IBN SINA Pharmaceutical Industry  (DHA:IBNSINA) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, The IBN SINA Pharmaceutical Industry's WACC % is 0.00%. The IBN SINA Pharmaceutical Industry's ROC % is 0.00% (calculated using TTM income statement data). The IBN SINA Pharmaceutical Industry earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

The IBN SINA Pharmaceutical Industry ROC % Related Terms

The IBN SINA Pharmaceutical Industry ROC % Historical Data

* Premium members only.

The historical data trend for The IBN SINA Pharmaceutical Industry's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The IBN SINA Pharmaceutical Industry ROC % Chart

The IBN SINA Pharmaceutical Industry Annual Data
Trend
ROC %

The IBN SINA Pharmaceutical Industry Semi-Annual Data
ROC %
DHA:IBNSINA
20GF Score
The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The IBN SINA Pharmaceutical Industry ROC % Calculation

The IBN SINA Pharmaceutical Industry's annualized Return on Capital (ROC %) for the fiscal year that ended in . 20 is calculated as:

ROC % (A: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: . 20 ) + Invested Capital (A: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(A: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(A: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

The IBN SINA Pharmaceutical Industry's annualized Return on Capital (ROC %) for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 0.00% mean?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a ROC % of 0.00% as of . 20. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on The IBN SINA Pharmaceutical Industry and its competitors.
Is The IBN SINA Pharmaceutical Industry's ROC % too high?
The IBN SINA Pharmaceutical Industry's current ROC % is 0.00%. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's ROC % compare to IMNPQ?
The IBN SINA Pharmaceutical Industry's ROC % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The IBN SINA Pharmaceutical Industry's current ROC % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a current ROC % of 0.00%. The current ROC % is 0.00%. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current ROC % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The IBN SINA Pharmaceutical Industry Business Description

Address Mirpur Road, Tanin Center, 3 Asad Gate, Mohammadpur, Dhaka, BGD, 1207
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
20GF Score

Get the complete analysis for DHA:IBNSINA

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT318.20
Price